{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T06:31:16Z","timestamp":1786516276797,"version":"build-2736575974"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Heart failure (HF) is highly prevalent among middle-aged and older adults and remains associated with substantial residual morbidity and mortality despite guideline-guided treatment. Previous meta-analyses of Qiliqiangxin Capsule (QLQX) have mainly focused on general HF populations or patients with HF with reduced ejection fraction (HFrEF), with limited attention to age-related clinical applicability. Therefore, this study evaluated the adjunctive effects of QLQX in predominantly middle-aged and older study populations with HF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy of QLQX combined with conventional therapies (CTs) on cardiac function in middle-aged and older HF patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Seven databases were searched from inception to January 2026 for RCTs of QLQX. Two reviewers independently screened studies and extracted data. The risk of bias and the certainty of the evidence were assessed using the Cochrane risk-of-bias tool and GRADE. Meta-analysis used random-effects models for continuous outcomes and fixed-effects models for dichotomous outcomes when heterogeneity was low. Subgroup and sensitivity analyses explored heterogeneity and tested robustness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eleven RCTs involving 4,642 participants were included. Compared with CTs alone or placebo plus CTs, QLQX combined with CTs was associated with higher LVEF across 10 trials involving 1,532 participants [MD\u2009=\u20095.77, 95% CI (4.32, 7.22)] and lower NT-proBNP levels [MD\u2009=\u2009\u2212312.98 pg\/mL, 95% CI (\u2212418.31, \u2212207.64)]. The pooled estimate also favored QLQX for LVEDD [MD\u2009=\u2009\u22123.50, 95% CI (\u22124.65, \u22122.35)]. HF hospitalization or rehospitalization was reported in two trials, and the pooled cumulative risk estimate favored QLQX [RR\u2009=\u20090.80, 95% CI (0.69, 0.93)]. However, these findings should be interpreted with caution because substantial heterogeneity was observed across several outcomes, follow-up durations varied across studies, and evidence for hard clinical endpoints remained limited, with outcome-specific certainty ranging from moderate to very low.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>QLQX combined with CTs may be associated with short- to medium-term improvements in surrogate measures of cardiac function and functional status in predominantly middle-aged and older study populations with HF. However, evidence regarding hard clinical endpoints remains limited, and large-scale, multicenter, high-quality, double-blind RCTs are needed to clarify its long-term efficacy and prognostic value.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420261295659<\/jats:ext-link>\n                      , identifier CRD420261295659.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1881321","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:57:17Z","timestamp":1786514237000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjunctive qiliqiangxin capsule for heart failure in predominantly middle-aged and older adults: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"13","author":[{"given":"Shun","family":"Han","sequence":"first","affiliation":[{"name":"Shaanxi University of Chinese Medicine","place":["Xianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Li","sequence":"additional","affiliation":[{"name":"Shaanxi University of Chinese Medicine","place":["Xianyang, China"]},{"name":"Department of Cardiology, The Affiliated Hospital of Shaanxi University of Chinese Medicine","place":["Xianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Gao","sequence":"additional","affiliation":[{"name":"Shaanxi University of Chinese Medicine","place":["Xianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebin","family":"Chen","sequence":"additional","affiliation":[{"name":"Shaanxi University of Chinese Medicine","place":["Xianyang, China"]},{"name":"Department of Cardiology, The Affiliated Hospital of Shaanxi University of Chinese Medicine","place":["Xianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41569-024-01046-6","article-title":"Global epidemiology of heart failure","volume":"21","author":"Khan","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1093\/eurheartj\/ehaf323","article-title":"Heart failure: assessment of the global economic burden","volume":"46","author":"Darvish","year":"2025","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1186\/s12872-023-03527-x","article-title":"Relationship between comorbidity and health outcomes in patients with heart failure: a systematic review and meta-analysis","volume":"23","author":"Lee","year":"2023","journal-title":"BMC Cardiovasc Disord"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.15420\/cfr.2024.37","article-title":"Pharmacological therapy of HFrEF in 2025: navigating new advances and old unmet needs in an eternal balance between progress and perplexities","volume":"11","author":"Mapelli","year":"2025","journal-title":"Card Fail Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1016\/j.jacc.2017.04.041","article-title":"Traditional Chinese medicine for cardiovascular disease: evidence and potential mechanisms","volume":"69","author":"Hao","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"155472","DOI":"10.1016\/j.phymed.2024.155472","article-title":"Traditional Chinese medicine and mitophagy: a novel approach for cardiovascular disease management","volume":"128","author":"Wang","year":"2024","journal-title":"Phytomedicine"},{"key":"B7","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1186\/s12872-024-04423-8","article-title":"Research on the mechanism of the anti-myocardial infarction effect of the Qiliqiangxin capsule on heart failure rats via nontargeted metabolomics and lipidomics","volume":"24","author":"Liu","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"key":"B8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.26599\/1671-5411.2025.03.002","article-title":"Chinese Guidelines for the diagnosis and treatment of heart failure 2024","volume":"22","author":"Zhang","year":"2025","journal-title":"J Geriatr Cardiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"121175","DOI":"10.1016\/j.jep.2026.121175","article-title":"Efficacy and safety of Qiliqiangxin capsule as adjunctive therapy in heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials","volume":"360","author":"Li","year":"2026","journal-title":"J Ethnopharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1002\/ejhf.3068","article-title":"Qiliqiangxin: a multifaceted holistic treatment for heart failure or a pharmacological probe for the identification of cardioprotective mechanisms?","volume":"25","author":"Packer","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"B11","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0091415017752941","article-title":"Subjective age and its correlates among middle-aged and older adults","volume":"88","author":"Shinan-Altman","year":"2019","journal-title":"Int J Aging Hum Dev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's Tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Br Med J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"Br Med J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-024-03169-2","article-title":"The traditional Chinese medicine Qiliqiangxin in heart failure with reduced ejection fraction: a randomized, double-blind, placebo-controlled trial","volume":"30","author":"Cheang","year":"2024","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.jacc.2013.05.035","article-title":"A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of Qili Qiangxin capsules in patients with chronic heart failure","volume":"62","author":"Li","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"B19","first-page":"1186","article-title":"Observation on Qiliqiangxin capsules in the treatment of chronic heart failure","volume":"17","author":"Gao","year":"2017","journal-title":"Eval Anal Drug-Use Hosp China"},{"key":"B20","first-page":"1208","article-title":"Analysis of changes in procalcitonin, N-terminal pro-brain natriuretic peptide levels, and echocardiographic parameters in patients with systolic heart failure","volume":"18","author":"Li","year":"2019","journal-title":"Chin J Difficult Complic Cases"},{"key":"B21","first-page":"2167","article-title":"Clinical observation of adjunctive treatment with Qili Qiangxin Capsules for chronic heart failure","volume":"41","author":"Wang","year":"2025","journal-title":"J Pract Tradit Chin Med"},{"key":"B22","first-page":"1305","article-title":"Efficacy of Qili Qiangxin Capsules combined with Western medicine in patients with coronary heart disease and heart failure","volume":"32","author":"Weng","year":"2019","journal-title":"Heilongjiang Med J"},{"key":"B23","first-page":"1658","article-title":"Effect of Qili Qiangxin capsules on cardiac function in patients with coronary heart disease complicated by heart failure","volume":"26","author":"Yang","year":"2017","journal-title":"Mod J Integr Tradit Chin West Med"},{"key":"B24","first-page":"55","article-title":"Clinical efficacy of Qili Qiangxin capsules in older patients with chronic heart failure","volume":"14","author":"Chen","year":"2021","journal-title":"Chin J Clin Ration Drug Use"},{"key":"B25","first-page":"442","article-title":"Effects of Qili Qiangxin capsule based on basic therapy on HR, LVEF, and LVEDD levels in patients with chronic congestive heart failure","volume":"14","author":"Liu","year":"2019","journal-title":"World Chin Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1605944","DOI":"10.3389\/fphar.2025.1605944","article-title":"Qili Qiangxin ameliorates chronic heart failure: a randomized clinical trial of biomarkers, inflammation, and cardiac outcomes","volume":"16","author":"Zhu","year":"2025","journal-title":"Front Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1001\/jama.2020.12698","article-title":"Estimating risk ratios and risk differences: alternatives to odds ratios","volume":"324","author":"Holmberg","year":"2020","journal-title":"JAMA"},{"key":"B28","doi-asserted-by":"publisher","first-page":"20190976","DOI":"10.1259\/bjr.20190976","article-title":"The choice and definition of summary measure for meta-analysis of clinical studies with binary outcomes: effect on clinical interpretation","volume":"93","author":"Plumb","year":"2020","journal-title":"Br J Radiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13643-025-02752-z","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis: updated guidance","volume":"14","author":"Tierney","year":"2025","journal-title":"Syst Rev"},{"key":"B30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res Synth Methods"},{"key":"B31","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Br Med J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/bmj.316.7129.469","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"316","author":"Stuck","year":"1998","journal-title":"BMJ"},{"key":"B33","first-page":"129","article-title":"Qili Qiangxin capsules combined with Western medicine for chronic heart failure: a randomized parallel controlled study","volume":"27","author":"Mao","year":"2013","journal-title":"J Pract Tradit Chin Intern Med"},{"key":"B34","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/9781119536604.ch10","article-title":"Analysing data and undertaking meta-analyses","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Deeks","year":"2019"},{"key":"B35","doi-asserted-by":"publisher","first-page":"156828","DOI":"10.1016\/j.phymed.2025.156828","article-title":"Deciphering the molecular mechanisms of QLQX capsules in heart failure: a multi-omics perspective","volume":"143","author":"Hao","year":"2025","journal-title":"Phytomedicine"},{"key":"B36","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.joim.2022.04.005","article-title":"Qili Qiangxin, a compound herbal medicine formula, alleviates hypoxia-reoxygenation-induced apoptotic and autophagic cell death via suppression of the ROS\/AMPK\/mTOR pathway in vitro","volume":"20","author":"Fan","year":"2022","journal-title":"J Integr Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1276195","DOI":"10.1155\/2020\/1276195","article-title":"Qiliqiangxin improves cardiac function through regulating energy metabolism via HIF-1\u03b1-dependent and independent mechanisms in heart failure rats after acute myocardial infarction","volume":"2020","author":"Wang","year":"2020","journal-title":"Biomed Res Int"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1881321\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:57:19Z","timestamp":1786514239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1881321\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":37,"alternative-id":["10.3389\/fcvm.2026.1881321"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1881321","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1881321"}}